The study aimed to investigate the relationship between the expression of secreted protein CD166/activated leukocyte cell adhesion molecule (ALCAM) and the sensitivity of NPC radiotherapy, and to identify whether it could be used as a biomarker for predicting the response of NPC to radiotherapy. This evidence concerns the gene ALCAM and nasopharyngeal carcinoma.